Amgen Company Profile (NASDAQ:AMGN)

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AMGN
  • CUSIP: 03116210
  • Web:
  • Market Cap: $135.95302 billion
  • Outstanding Shares: 729,674,000
Average Prices:
  • 50 Day Moving Avg: $175.99
  • 200 Day Moving Avg: $169.31
  • 52 Week Range: $133.64 - $191.10
  • Trailing P/E Ratio: 17.14
  • Foreward P/E Ratio: 14.79
  • P/E Growth: 3.63
Sales & Book Value:
  • Annual Revenue: $23.05 billion
  • Price / Sales: 5.96
  • Book Value: $43.41 per share
  • Price / Book: 4.33
  • Annual Dividend: $4.60
  • Dividend Yield: 2.5%
  • EBIDTA: $12.36 billion
  • Net Margins: 35.46%
  • Return on Equity: 29.85%
  • Return on Assets: 11.72%
  • Debt-to-Equity Ratio: 1.06%
  • Current Ratio: 6.20%
  • Quick Ratio: 5.82%
  • Average Volume: 2.81 million shs.
  • Beta: 1.35
  • Short Ratio: 2.81

Frequently Asked Questions for Amgen (NASDAQ:AMGN)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Friday, July 28th. Stockholders of record on Thursday, August 17th will be paid a dividend of $1.15 per share on Friday, September 8th. This represents a $4.60 annualized dividend and a dividend yield of 2.44%. The ex-dividend date of this dividend is Tuesday, August 15th. View Amgen's Dividend History.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Tuesday, July, 25th. The company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company's quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.84 EPS. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Amgen.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

21 brokers have issued 1 year target prices for Amgen's shares. Their predictions range from $161.00 to $209.00. On average, they anticipate Amgen's share price to reach $186.83 in the next twelve months. View Analyst Ratings for Amgen.

What are analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. Cann analysts commented, "Amgen announced today positive results from a new Repatha (evolocumab) analysis of cardiovascular outcomes study (FOURIER) that showed a statistically significant relationship between lower achieved low-density lipoprotein cholesterol (LDL-C) levels and lower cardiovascular event rates in patients with established atherosclerotic cardiovascular disease. Importantly, there was no evidence of a leveling off of effect and no new safety concerns were identified in this analysis." (8/28/2017)
  • 2. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
  • 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
  • David W. Meline, Executive Vice President, Chief Financial Officer
  • Sean E. Harper, Executive Vice President - Research and Development
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives
  • Esteban Santos, Executive Vice President, Operations
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
  • Lori A. Johnston, Senior Vice President
  • David A. Piacquad, Senior Vice President - Business Development

Who owns Amgen stock?

Amgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (7.81%), Capital Research Global Investors (7.37%), Vanguard Group Inc. (7.15%), BlackRock Inc. (6.78%), State Street Corp (4.53%) and Northern Trust Corp (1.27%). Company insiders that own Amgen stock include Annette Louise Such, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, AJO LP, Standard Life Investments LTD, State Street Corp, FIL Ltd, American Century Companies Inc., Bank of New York Mellon Corp and Bank of Nova Scotia. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Renaissance Technologies LLC, BlackRock Inc., Nordea Investment Management AB, Parametric Portfolio Associates LLC, Ameriprise Financial Inc. and Canada Pension Plan Investment Board. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $188.17.

MarketBeat Community Rating for Amgen (NASDAQ AMGN)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  972 (Vote Outperform)
Underperform Votes:  584 (Vote Underperform)
Total Votes:  1,556
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 11 Hold Ratings, 9 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.52)
Consensus Price Target: $186.83 (0.71% downside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$192.00HighView Rating Details
9/7/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$203.00LowView Rating Details
8/28/2017CannReiterated RatingBuyLowView Rating Details
8/21/2017MizuhoReiterated RatingBuy$195.00 -> $183.00LowView Rating Details
7/27/2017ArgusBoost Price TargetBuy$180.00 -> $195.00LowView Rating Details
7/26/2017Deutsche Bank AGReiterated RatingHold$172.00 -> $174.00LowView Rating Details
7/26/2017BMO Capital MarketsDowngradeOutperform -> Market PerformLowView Rating Details
7/22/2017Cowen and CompanyReiterated RatingOutperform$209.00LowView Rating Details
7/17/2017Jefferies Group LLCReiterated RatingBuy$195.00LowView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$177.00LowView Rating Details
7/10/2017Morgan StanleyReiterated RatingOverweightLowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$161.00LowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
3/20/2017Goldman Sachs Group, Inc. (The)Lower Price TargetConviction-Buy$208.00 -> $202.00LowView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$193.00LowView Rating Details
2/1/2017Bank of America CorporationUpgradeNeutral -> Buy$156.68 -> $192.00N/AView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00N/AView Rating Details
9/28/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00N/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00N/AView Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Amgen (NASDAQ:AMGN)
Earnings by Quarter for Amgen (NASDAQ:AMGN)
Earnings History by Quarter for Amgen (NASDAQ AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$3.11N/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.67 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$3.04$3.17$3.09
Q2 20173$3.05$3.12$3.09
Q3 20173$3.01$3.17$3.11
Q4 20173$2.97$2.99$2.98
Q1 20181$3.29$3.29$3.29
Q2 20181$3.18$3.18$3.18
Q3 20181$3.10$3.10$3.10
Q4 20181$3.10$3.10$3.10
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Most Recent Dividend:9/8/2017
Annual Dividend:$4.60
Dividend Yield:2.44%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:41.93% (Trailing 12 Months of Earnings)
36.86% (Based on This Year's Estimates)
36.16% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Dividend History by Quarter for Amgen (NASDAQ AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 78.09%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.80View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline logoAMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17 ... - PR Newswire (press release) - September 20 at 8:59 PM logoAMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17, 2017, Encouraged to Contact the Firm - September 20 at 8:59 PM logodeCODE Study Reveals an Ancient Achilles Heel in the Human Genome - September 20 at 3:58 PM logoIs Amgen (AMGN) a Great Stock for Value Investors? - - Nasdaq - September 19 at 3:49 PM logoAmgen and Allergan: Avastin Biosimilar Approval Part 2 - Seeking Alpha - September 19 at 3:49 PM logoFDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy - September 18 at 4:11 PM logoWe're not chasing electric utilities: Heartland Financial... - September 18 at 4:11 PM logoAmgen Could Rally Higher On This Breakout - Seeking Alpha - September 15 at 9:11 PM logoNew FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes - September 15 at 4:08 PM logoWhy Amgen, Lilly, J&J Are Interested In These Small Biotechs - September 15 at 4:08 PM logoA Biosimilar Cure for Sky-High Cancer Drug Prices - September 14 at 9:49 PM logoAmgen challenge to Genentech $6 billion cancer drug OK'd by FDA - San Francisco Business Times - September 14 at 9:26 PM logoAmgen Needs To Get Lucky With Repatha - Seeking Alpha - September 14 at 9:26 PM logoBiosimilar 2017 Progress Report: Stocks in Focus - September 14 at 9:26 PM logoFDA Approves First 'Biosimilar' for Cancer Treatment - September 14 at 9:26 PM logoAmgen Inc. (AMGN) Receives New Coverage from Analysts at Royal Bank Of Canada - September 14 at 5:26 PM logoNoteworthy Thursday Option Activity: AMGN, RCL, CVX - September 14 at 4:20 PM logoThe FDA just approved the first direct competitor to a billion-dollar cancer drug - September 14 at 4:20 PM logoUAB makes headway with new osteoporosis drug - September 14 at 4:20 PM logoU.S. FDA approves biosimilar version of cancer drug Avastin - September 14 at 4:20 PM logoAmgen, Inc. : AMGN-US: Dividend Analysis : August 17th, 2017 (record date) : By the numbers : September 14, 2017 - September 14 at 4:20 PM logoAmgen challenge to Genentech $6 billion cancer drug OK'd by FDA - September 14 at 4:20 PM logoAmgen Reaches Analyst Target Price - Nasdaq - September 13 at 9:59 PM logo5 Ways To Play 2017’s Biotech Boom - September 13 at 9:58 PM logoSupercharge Your Portfolio With Amgen, Inc. (AMGN) Stock - - September 12 at 9:06 PM logoAmgen Stock Breaks Out From Resistance - September 12 at 4:03 PM logo3 Things Amgen Inc.'s Management Just Said That You'll Want to Know - September 12 at 4:03 PM logoWhat Does Amgen Inc’s (AMGN) Share Price Indicate? - September 12 at 4:03 PM logoAmgen Builds on a Breakout - September 12 at 4:03 PM logo3 Things Amgen Inc.'s Management Just Said That You'll Want to Know - September 12 at 4:03 PM logoSupercharge Your Portfolio With Amgen, Inc. (AMGN) Stock - September 12 at 11:48 AM logoCarter Worth And Mike Khouw's Amgen Trade - Benzinga - September 12 at 2:46 AM logoOncoSec Seeks Accelerated Approval to Treat Melanoma - September 11 at 9:46 PM logoInteresting AMGN Put And Call Options For January 2020 - September 11 at 4:45 PM logoWhat’s Gilead Sciences’ Valuation? - September 11 at 4:45 PM logoEVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine - September 11 at 4:45 PM logoAmgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference - September 11 at 4:45 PM logoThe ‘greatest stock of all time’ just came back to life: Technician - September 11 at 1:16 PM logoZacks: Brokerages Expect Amgen Inc. (AMGN) Will Post Quarterly Sales of $5.73 Billion - September 10 at 9:20 AM logoAmgen Inc. (AMGN) Given Average Recommendation of "Buy" by Analysts - September 9 at 8:38 PM logoAmgen Highlights The Latest EVENITY™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting - September 8 at 4:13 PM logoNew AstraZeneca, Amgen drug looks strong rival in severe asthma - September 7 at 8:55 PM logoAstraZeneca's COPD Candidate Duaklir Reports Positive Data - September 7 at 8:55 PM logoAmgen To Present At The Morgan Stanley Global Healthcare Conference - September 7 at 8:55 PM logoNew Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies - September 7 at 8:55 PM logoAmgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise - Nasdaq - September 7 at 3:49 PM logoNoteworthy Thursday Option Activity: AMGN, CVX, CMCSA - Nasdaq - September 7 at 3:49 PM logoAmgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise - September 7 at 3:49 PM logoOppenheimer Holdings, Inc. Reaffirms "Buy" Rating for Amgen Inc. (AMGN) - September 7 at 3:26 PM logoNew AstraZeneca, Amgen biotech drug offers broad asthma relief - September 6 at 8:48 PM



Amgen (AMGN) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff